Scholarlink

Introduction <p>Nivolumab is approved in France as monotherapy for the treatment of advanced (locally advanced or metastatic) non-small cell lung cancer (aNSCLC) after prior chemotherapy. The Lung Initiative on Sequence Therapy (LIST) study is evaluating the real-world effectiveness, safety and immunotherapy-rechallenge outcomes with nivolumab in previously treated French patients with aNSCLC.</p> Methods <p>This longitudinal, prospective, observational study enrolled patients with aNSCLC who received ≥ 1 prior line of treatment that included chemotherapy. Three patient cohorts, based on prior treatment, were assessed: immunotherapy-naïve (cohort&#xa0;1; prior chemotherapy, no prior immunotherapy), and immunotherapy-experienced, including patients who discontinued prior immunotherapy for reasons other than immunotherapy-related toxicity (cohort&#xa0;2) and those who discontinued because of immunotherapy-related toxicity (cohort&#xa0;3). The primary endpoint was time to treatment discontinuation (TTD). Results after at least 12&#xa0;months of follow-up are reported.</p> Results <p>At data cut-off (September 2024), 522 patients were enrolled. In cohort&#xa0;1 (<i>N</i> = 280), cohort&#xa0;2 (<i>N</i> = 197) and cohort&#xa0;3 (<i>N</i> = 45), the 12-month TTD rate was 17.7% (95%&#xa0;CI 13.4, 22.5), 14.4% (95%&#xa0;CI 9.8, 19.8) and 16.7% (95%&#xa0;CI 7.3, 29.2), respectively. The main reason for nivolumab discontinuation was disease progression. Younger patients, those with better performance status (PS), longer prior immunotherapy duration and prolonged benefit with prior immunotherapy had numerically higher discontinuation-free rates. Median PFS was 3.2, 2.7 and 3.9&#xa0;months (95%&#xa0;CI 2.7–4.1, 2.2–3.4, 2.2–7.4), and median overall survival (OS) was 12.3, 9.5 and 10.4&#xa0;months (95%&#xa0;CI 8.6–13.7, 7.2–11.3, 7.6–20.1) in cohorts&#xa0;1, 2 and 3, respectively. Any-grade treatment-related adverse events were reported in 36.1%, 25.0% and 37.0% of patients in the respective cohorts.</p> Conclusions <p>The 1-year results of LIST show consistent effectiveness and safety of nivolumab in immunotherapy-experienced patients, especially in specific subgroups. Nivolumab safety in patients with prior immunotherapy-related toxicity appeared to be consistent with its expected safety profile.</p> Trial Registration <p>ClinicalTrials.gov identifier NCT04500535.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Real-World Use and Immunotherapy Rechallenge Outcomes with Nivolumab in Advanced Non-small Cell Lung Cancer in France: Interim Results of the LIST Study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月14日

查看全文
  • Benoît Godbert,
  • Elisa Gobbini,
  • Chantal Decroisette,
  • Hervé Lena,
  • Yaacoub Khalife,
  • Florence Brellier,
  • Anne Fleuriet,
  • Maeva Zysman,
  • Thomas Egenod,
  • Denis Moro Sibilot,
  • Nicolas Girard

摘要

Introduction

Nivolumab is approved in France as monotherapy for the treatment of advanced (locally advanced or metastatic) non-small cell lung cancer (aNSCLC) after prior chemotherapy. The Lung Initiative on Sequence Therapy (LIST) study is evaluating the real-world effectiveness, safety and immunotherapy-rechallenge outcomes with nivolumab in previously treated French patients with aNSCLC.

Methods

This longitudinal, prospective, observational study enrolled patients with aNSCLC who received ≥ 1 prior line of treatment that included chemotherapy. Three patient cohorts, based on prior treatment, were assessed: immunotherapy-naïve (cohort 1; prior chemotherapy, no prior immunotherapy), and immunotherapy-experienced, including patients who discontinued prior immunotherapy for reasons other than immunotherapy-related toxicity (cohort 2) and those who discontinued because of immunotherapy-related toxicity (cohort 3). The primary endpoint was time to treatment discontinuation (TTD). Results after at least 12 months of follow-up are reported.

Results

At data cut-off (September 2024), 522 patients were enrolled. In cohort 1 (N = 280), cohort 2 (N = 197) and cohort 3 (N = 45), the 12-month TTD rate was 17.7% (95% CI 13.4, 22.5), 14.4% (95% CI 9.8, 19.8) and 16.7% (95% CI 7.3, 29.2), respectively. The main reason for nivolumab discontinuation was disease progression. Younger patients, those with better performance status (PS), longer prior immunotherapy duration and prolonged benefit with prior immunotherapy had numerically higher discontinuation-free rates. Median PFS was 3.2, 2.7 and 3.9 months (95% CI 2.7–4.1, 2.2–3.4, 2.2–7.4), and median overall survival (OS) was 12.3, 9.5 and 10.4 months (95% CI 8.6–13.7, 7.2–11.3, 7.6–20.1) in cohorts 1, 2 and 3, respectively. Any-grade treatment-related adverse events were reported in 36.1%, 25.0% and 37.0% of patients in the respective cohorts.

Conclusions

The 1-year results of LIST show consistent effectiveness and safety of nivolumab in immunotherapy-experienced patients, especially in specific subgroups. Nivolumab safety in patients with prior immunotherapy-related toxicity appeared to be consistent with its expected safety profile.

Trial Registration

ClinicalTrials.gov identifier NCT04500535.